Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Amortizatization of Intangibles (2022 - 2026)

Catalyst Pharmaceuticals filings provide 5 years of Amortizatization of Intangibles readings, the most recent being $9.7 million for Q1 2026.

  • On a quarterly basis, Amortizatization of Intangibles rose 16071.67% to $9.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $48.3 million, a 7.96% decrease, with the full-year FY2025 number at $37.5 million, changed 0.32% from a year prior.
  • Amortizatization of Intangibles hit $9.7 million in Q1 2026 for Catalyst Pharmaceuticals, down from $37.3 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $37.3 million in Q4 2025 to a low of -$535000.0 in Q4 2022.
  • Median Amortizatization of Intangibles over the past 5 years was $4.4 million (2023), compared with a mean of $8.3 million.
  • Biggest five-year swings in Amortizatization of Intangibles: skyrocketed 21123.56% in 2024 and later crashed 93.67% in 2025.
  • Catalyst Pharmaceuticals' Amortizatization of Intangibles stood at -$535000.0 in 2022, then skyrocketed by 67.48% to -$174000.0 in 2023, then skyrocketed by 21123.56% to $36.6 million in 2024, then increased by 1.87% to $37.3 million in 2025, then plummeted by 73.96% to $9.7 million in 2026.
  • The last three reported values for Amortizatization of Intangibles were $9.7 million (Q1 2026), $37.3 million (Q4 2025), and $500000.0 (Q3 2025) per Business Quant data.